Refine
Has Fulltext
- yes (12)
Document Type
- Journal article (12)
Language
- English (12)
Keywords
- ALS (2)
- amyotrophic lateral sclerosis (2)
- amyotrophic lateral sclerosis (ALS) (2)
- caregiver burden (2)
- coping (2)
- depression (2)
- disease progression (2)
- frontotemporal dementia (2)
- quality of life (QoL) (2)
- well-being (2)
- ALS treatment (1)
- Alien limb syndrome (1)
- Amyotrophic Lateral Sclerosis (ALS) (1)
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) (1)
- Anarchic limb syndrome (1)
- CSVD (1)
- Corticobasal syndrome (1)
- Diagnosis prediction (1)
- ESM (1)
- EuroQol Five Dimension Five Level Scale (EQ-5D-5L) (1)
- GFAP (1)
- PPAR-gamme (1)
- SOD1 mutations (1)
- Support vector machine (1)
- anxiety (1)
- aphasia (1)
- assessment of cognitive disorders/dementia (1)
- assistive devices (1)
- atlas‐based volumetry (1)
- biomarker (1)
- care (1)
- caregiver (1)
- central nervous system (1)
- chitinase-3-like protein 1 (1)
- cognitive neuropsychology in dementia (1)
- decreasing autonomy (1)
- delays progression (1)
- diagnostic markers (1)
- ethics (1)
- experience sampling (1)
- functional status (1)
- genome-wide association studies (1)
- health-related quality of life (1)
- health-related quality of life (HRQoL) (1)
- hexanucleotide repeat (1)
- informal caregiving (1)
- longitudinal magnetic resonance imaging (1)
- mental health (1)
- monocycline (1)
- neurofilaments (1)
- nonalcoholic steatohepatitis (1)
- patient reported outcome measures (1)
- primary progressive aphasia (1)
- psychiatric disorders (1)
- psychological support (1)
- psychosocial adaptation (1)
- quality of life (1)
- reminiscence (1)
- rumination (1)
- sample size calculation (1)
- socioeconomic status (1)
- spinal muscular atrophy (1)
- symptom-specific treatment (1)
- transgenic mouse model (1)
- volumetric MRI (1)
- white matter hyperintensities (1)
- “bulbar-onset” ALS (bALS) (1)
- “limb-onset” ALS (lALS) (1)
Institute
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects 1 in ~350 individuals. Genetic association studies have established ALS as a multifactorial disease with heritability estimated at ~61%, and recent studies show a prominent role for rare variation in its genetic architecture. To identify rare variants associated with disease onset we performed exome array genotyping in 4,244 cases and 3,106 controls from European cohorts. In this largest exome-wide study of rare variants in ALS to date, we performed single-variant association testing, gene-based burden, and exome-wide individual set-unique burden (ISUB) testing to identify single or aggregated rare variation that modifies disease risk. In single-variant testing no variants reached exome-wide significance, likely due to limited statistical power. Gene-based burden testing of rare non-synonymous and loss-of-function variants showed NEK1 as the top associated gene. ISUB analysis did not show an increased exome-wide burden of deleterious variants in patients, possibly suggesting a more region-specific role for rare variation. Complete summary statistics are released publicly. This study did not implicate new risk loci, emphasizing the immediate need for future large-scale collaborations in ALS that will expand available sample sizes, increase genome coverage, and improve our ability to detect rare variants associated to ALS.
C9ORF72 mutations are the most common cause of familial frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). MRI studies have investigated structural changes in C9ORF72-associated FTLD (C9FTLD) and provided first insights about a prominent involvement of the thalamus and the cerebellum. Our multicenter, 18F-fluorodeoxyglucose positron-emission tomography study of 22 mutation carriers with FTLD, 22 matched non-carriers with FTLD, and 23 cognitively healthy controls provided valuable insights into functional changes in C9FTLD: compared to non-carriers, mutation carriers showed a significant reduction of glucose metabolism in both thalami, underscoring the key role of the thalamus in C9FTLD. Thalamic metabolism did not correlate with disease severity, duration of disease, or the presence of psychotic symptoms. Against our expectations we could not demonstrate a cerebellar hypometabolism in carriers or non-carriers. Future imaging and neuropathological studies in large patient cohorts are required to further elucidate the central role of the thalamus in C9FTLD.